Media about us

20 September 2016

Allergan to buy Tobira in push for NASH treatments

Natalie Grover / Reuters

Allergan Plc (AGN.N) said it would buy Tobira Therapeutics Inc (TBRA.O) in a deal worth up to $1.7 billion, about 19 times the company's current value, to get a leg up in the race to develop therapies for NASH, an incurable fatty liver disease.

20 September 2016

Acquisitive Allergan buys micro-cap NASH biotech Tobira months

Ben Adams / Fierce Biotech

On the back of a number of deals in recent months, mainly in dermatology and after dodging its own $100 billion-plus consumption by Pfizer ($PFE) this year, Allergan ($AGN) has snapped up tiny Tobira ($TBRA) and its struggling fatty liver disease candidate, along with the rest of its pipeline, for potentially $1.7 billion.

16 September 2016

No More Reading Glasses? New Implant May Help With Aging Eyes

NBC NEWS

The Raindrop implant reshapes the cornea to correct nearsightedness. Cheri Eckstadt, of Minnesota, is about to become the first person in the nation to get the newly-approved FDA device.

16 September 2016

So long, reading glasses? New Raindrop eye implant could make them obsolete

Today

Thanks to a new eye implant called the Raindrop, a five-minute procedure could make reading glasses a thing of the past. NBC News medical contributor Dr. John Torres reports on the first patient to undergo the procedure since it received FDA approval.

12 September 2016

Pfizer goes local with Russian joint venture - Doing Business With Russia

Kira Egorova / Doing Business With Russia

The American pharmaceutical corporation is building a new facility south of Moscow to capitalize on support from government initiatives, which is also indicative of its commitment to the local market. 

07 September 2016

Pfizer goes local with Russian joint venture

Kira Egorova / Russia Beyond the Headlines

In July 2016, the U.S. pharmaceutical giant Pfizer became the first foreign company in its sector to localize its business in Russia with a Russian partner. Pfizer and the Russian-American company NovaMedica, whose shareholders include the Russian state-owned company Rusnano, decided to jointly invest in the construction of a plant in the Kaluga Region, 125 miles southwest of Moscow.

01 September 2016

FDA-Approved Raindrop Near Vision Inlay Corrects Blurry Reading Vision -- Now Available in Utah for the First Time

Yahoo Finance

Most people begin to notice a decline in their near vision in their early 40s and 50s, which typically occurs as a result of a frustrating but inevitable age-related change in vision called presbyopia. Fortunately, recent advancements in technology provide surgical options to improve near vision and offer patients restored visual independence. On June 29, 2016, The U.S. Food and Drug Administration (FDA) approved the Raindrop® Near Vision Inlay -- a surgical implant produced by ReVision Optics, Inc. -- used to help improve near vision in patients between the ages of 45-65 years old who suffer from presbyopia.

23 August 2016

Jeffrey Whitman, M.D., Will Be the First Dallas Eye Doctor to Implant Commercial Raindrop® Near Vision Inlays in U.S.

PRWEB

Following extensive clinical trials, the Food and Drug Administration (FDA) approved the Raindrop Near Vision Inlay, a tiny, clear, implantable medical device, to improve near vision in some patients with presbyopia. FDA approval was granted June 29, 2016.

11 August 2016

Follow the Money: US Companies Shrug Off Politics and Invest in Russia

Sputnik

In spite of the US government's best efforts to sanction the Russian economy, many US companies are continuing or even increasing their investment in Russia, wrote Forbes columnist Kenneth Rapoza.

05 August 2016

American Companies Thriving In Russia: Is There Something To Be Ashamed About?

Kenneth Rapoza / Forbes

Ever since the Democratic National Committee decided to turn their disdain for Bernie Sanders into disdain for Russians and Donald Trump, the New York billionaire has been seen as being in bed with Russian oligarchs and longing to cut deals in Moscow. Since when was it so bad to want to do business with the Russians?